To address this limitation, ICG has been conjugated with targeted agents to develop novel markers: ICG‐labelled c‐MET‐binding peptide targets tumours via c‐MET binding [23], whilst ONM‐100/pegsitacianine is activated by the acidic extracellular environment associated with solid tumours [35, 36, 78]. Here, MET is linked to neoplasm.